Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Beraprost. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR known ✓ | P43119 | 4/20 | 0.85 |
| ▸ | PTGER3 | P43115 | 13/20 | 0.53 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.53 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.53 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.53 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.39 |
| ▸ | PTGFR | P43088 | 12/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Beraprost SCHEMBL11946708 | 1.00 | PTGIR (0.85) | PTGIRPTGER3PTGER2PTGER1PTGDR | |
| Beraprost SCHEMBL1554142 | 1.00 | PTGIR (0.85) | PTGIRPTGER3PTGER2PTGER1PTGDR | |
| Beraprost SCHEMBL16904620 | 1.00 | PTGIR (0.85) | PTGIRPTGER3PTGER2PTGER1PTGDR | |
| Beraprost SCHEMBL4754473 | 1.00 | PTGIR (0.85) | PTGIRPTGER3PTGER2PTGER1PTGDR | |
| Beraprost SCHEMBL16405382 | 1.00 | PTGIR (0.85) | PTGIRPTGER3PTGER2PTGER1PTGDR | |
| Beraprost SCHEMBL6084946 | 1.00 | PTGIR (0.85) | PTGIRPTGER3PTGER2PTGER1PTGDR | |
| Beraprost SCHEMBL16894023 | 1.00 | PTGIR (0.85) | PTGIRPTGER3PTGER2PTGER1PTGDR | |
| Beraprost SCHEMBL22972690 | 1.00 | PTGIR (0.85) | PTGIRPTGER3PTGER2PTGER1PTGDR | |
| Beraprost SCHEMBL21778834 | 1.00 | PTGIR (0.85) | PTGIRPTGER3PTGER2PTGER1PTGDR | |
| Beraprost SCHEMBL19113984 | 1.00 | PTGIR (0.85) | PTGIRPTGER3PTGER2PTGER1PTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240082154-A1 | DISEASE-SITE-SPECIFIC LIPOSOMAL FORMULATION | CUORIPS INC. (JP) | 2024-03-14 | — | — | US | claimed |
| US-20210113464-A1 | DISEASE-SITE-SPECIFIC LIPOSOMAL FORMULATION | CUORIPS INC. (JP) | 2021-04-22 | — | — | US | claimed |
| US-20150231312-A1 | Advanced Heart Failure Treatment Material as Myocardial/Cardiovascular Regeneration Device | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-08-20 | — | — | US | claimed |
| US-20150196578-A1 | COMBINATION THERAPY TREATMENT FOR VIRAL INFECTIONS | GEMMUS PHARMA INC (US) | 2015-07-16 | — | — | US | claimed |
| US-20120190637-A1 | COMBINATION THERAPY TREATMENT FOR VIRAL INFECTIONS | GEMMUS PHARMA, INC. (US) | 2012-07-26 | — | — | US | claimed |
| US-20240082154-A1 | DISEASE-SITE-SPECIFIC LIPOSOMAL FORMULATION | CUORIPS INC. (JP) | 2024-03-14 | — | — | US | disclosed |
| EP-3718537-A1 | DISEASE-SITE-SPECIFIC LIPOSOMAL FORMULATION | Osaka University (JP) | 2020-10-07 | — | — | EP | disclosed |
| EP-2913047-B1 | PULMONARY DISEASE-SPECIFIC THERAPEUTIC AGENT | CARDIO INCORPORATED (JP) | 2019-05-08 | — | — | EP | disclosed |
| US-9597436-B2 | Advanced heart failure treatment material as myocardial/cardiovascular regeneration device | OSAKA UNIVERSITY (JP) | 2017-03-21 | — | — | US | disclosed |
| US-20150272874-A1 | PULMONARY DISEASE-SPECIFIC THERAPEUTIC AGENT | CARDIO INCORPORATED (JP) | 2015-10-01 | — | — | US | disclosed |
| EP-2913047-A1 | PULMONARY DISEASE-SPECIFIC THERAPEUTIC AGENT | Cardio, Inc. (JP) | 2015-09-02 | — | — | EP | disclosed |
| US-20150231312-A1 | Advanced Heart Failure Treatment Material as Myocardial/Cardiovascular Regeneration Device | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-08-20 | — | — | US | disclosed |
| EP-2898902-A1 | ADVANCED HEART FAILURE TREATMENT MATERIAL AS MYOCARDIAL/CARDIOVASCULAR REGENERATION DEVICE | Osaka University (JP) | 2015-07-29 | — | — | EP | disclosed |
| US-20150196578-A1 | COMBINATION THERAPY TREATMENT FOR VIRAL INFECTIONS | GEMMUS PHARMA INC (US) | 2015-07-16 | — | — | US | disclosed |
| EP-1913946-B1 | THERAPEUTIC AGENT AND TREATMENT METHOD FOR AMELIORATING UREMIA | TORAY INDUSTRIES (JP) | 2014-03-05 | — | — | EP | disclosed |
| US-20120190637-A1 | COMBINATION THERAPY TREATMENT FOR VIRAL INFECTIONS | GEMMUS PHARMA, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| EP-1913946-A1 | THERAPEUTIC AGENT AND TREATMENT METHOD FOR AMELIORATING UREMIA | TORAY INDUSTRIES, INC. (JP) | 2008-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150196578-A1 | COMBINATION THERAPY TREATMENT FOR VIRAL INFECTIONS | PTGER4, TMPRSS4, GPR4 | PTGIR 93/4885PTGER3 15/4885PTGER2 27/4885 |
| US-20150231312-A1 | Advanced Heart Failure Treatment Material as Myocardial/Cardiovascular Regeneration Device | TNNT2, TNNI3, MYLK2 | PTGIR 150/4885PTGER3 2450/4885PTGER2 1425/4885 |
| US-20210113464-A1 | DISEASE-SITE-SPECIFIC LIPOSOMAL FORMULATION | PTGDR2, PLA2R1, PTGDR | PTGIR 7/4885PTGER3 40/4885PTGER2 13/4885 |
| US-20120190637-A1 | COMBINATION THERAPY TREATMENT FOR VIRAL INFECTIONS | PTGER4, TMPRSS4, GPR4 | PTGIR 93/4885PTGER3 15/4885PTGER2 27/4885 |
| US-20150272874-A1 | PULMONARY DISEASE-SPECIFIC THERAPEUTIC AGENT | MRGPRX2, MRGPRX1, TSG101 | PTGIR 106/4885PTGER3 1928/4885PTGER2 1586/4885 |
| US-20240082154-A1 | DISEASE-SITE-SPECIFIC LIPOSOMAL FORMULATION | LPAR2, PLA2R1, PTGDR2 | PTGIR 10/4885PTGER3 44/4885PTGER2 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.